A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults

• Status: Completed
• Trial end date: 2018-05-23
• Target enrollment: 0
• Participant gender: All

Summary

This study is to assess the bioequivalence of a test formulation of vadadustat (A) compared to a reference formulation of vadadustat (B)

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Akebia Therapeutics
• Treatments: Glycine

Criteria

Inclusion Criteria:

• Between 18 and 55 years of age, inclusive, at time of informed consent.

• Healthy subjects per Investigator judgment as documented by the medical history, physical examination, vital sign assessments, 12-lead electrocardiogram (ECG), clinical laboratory assessments, and general observations.

• Minimum weight of 45 kg with Body mass index (BMI) between 18 and 29.5 kg/m2, inclusive.

• Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure

• Willing and able to comply with the requirements of the study protocol.

Exclusion Criteria:

• Current or past history of cardiovascular, cerebrovascular, pulmonary, gastrointestinal, hematologic, renal, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, or other major disease, history of cancer (except non-melanoma skin cancer) or history of chemotherapy use.

• Any surgical or medical condition or history that may potentially alter the absorption, metabolism, or excretion of study treatment, such as, but not limited to gastric bypass surgery or gastric or duodenal ulcers.

• History of severe allergic or anaphylactic reactions.

• Chronic daily medication use.

• History of drug abuse

• Excessive alcohol consumption

• Smoking and the use of nicotine-containing products

• Consumption of grapefruit or grapefruit juice, pomelo, star fruit, Seville or Moro (blood) orange, or their associated products

• Participation in another clinical trial or exposure to any investigational agent.

• Donation of blood or significant blood loss or plasma donation.

• Any condition that would interfere with the ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk.